New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 2, 2008, Pages 184-197

  Heal, D J ^a   Smith, S L ^a   Kulkarni, R S ^a   Rowley, H L ^a  

^a RenaSci Ltd   (United Kingdom)

Author keywords

ADHD; Amphetamine; Animal model; Attention deficit hyperactivity disorder; Dopamine; Methylphenidate; Microdialysis; Noradrenaline; Norepinephrine; SH rat; SHR; Spontaneously hypertensive rat

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; ATOMOXETINE; CENTEDRINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; GUANFACINE; INTUNIV; LISDEXAMFETAMINE; METHYLPHENIDATE; NORADRENALIN; PAROXETINE; WELBUTRIN;

ABDOMINAL PAIN; APPETITE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; BRAIN REGION; CATECHOLAMINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENANTIOMER; ENZYME INHIBITION; GENETIC ASSOCIATION; GROWTH RATE; HUMAN; HYPERTENSION; INSOMNIA; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; NAUSEA AND VOMITING; NEUROANATOMY; NEUROCHEMISTRY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; OUTBRED STRAIN; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPONTANEOUSLY HYPERTENSIVE RAT; TACHYCARDIA; TIC;

AMPHETAMINE; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; METHYLPHENIDATE; MICRODIALYSIS; NOREPINEPHRINE; PROPYLAMINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

ANIMALIA; RATTUS;

EID: 44649139827     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.03.016     Document Type: Review

References (129)

1. Adriani W., Caprioli A., Granstrem O., Carli M., and Laviola G. The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Neurosci Biobehav Rev 27 (2003) 639-651
2. Adriani W., Rea M., Baviera M., Invernizzi W., Carli M., Ghirardi O., et al. Acetyl-l-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacol 176 (2004) 296-304
3. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (1994), American Psychiatric Association, Arlington, VA
4. Andersen P.H. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166 (1989) 493-504
5. Aoyama T., Kotaki H., Sawada Y., and Iga T. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacol 127 (1996) 117-122
6. Arnold L.E., Wender P.H., McCloskey M.M., and Snyder S.H. Levoamphetamine and dextroamphetamine: comparative efficacy in hyperkinetic syndrome. Arch Gen Psychiatr 27 (1972) 816-822
7. Arnold L.E., Kirilcuk V., Samuel A., Corson A., and Corson E.O.L. Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs. Am J Psychiatr 130 (1973) 165-170
8. Arnold L.E., Huestis R.D., Smeltzer D.J., Scheib J., Wemmer D., and Colner G. Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Arch Gen Psychiatr 33 (1976) 292-301
9. Arnsten A.F., and Dudley A.G. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 1 (2005) 2
10. 3H]norepinephrine from isolated brain tissue. J Pharmacol Exp Ther 189 (1974) 110-118
11. Barkley R.A., Fischer M., Edelbrock C.S., and Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatr 29 (1990) 546-557
12. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F.T., Kelley A.E., Schmeichel B., et al. Methylphenidate preferentially increases catecholaminergic neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychatr 60 (2006) 111-120
13. Biederman J., Faraone S.V., Spencer T., Wilens T., Mick E., and Lapey K.A. Gender differences in a sample of adults with attention deficit hyperactivity disorder. Psychiatr Res 53 (1994) 13-29
14. Bizot J.C., Chenault N., Houzé B., Herpin A., David S., Pothion S., et al. Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats. Psychopharmacol 193 (2007) 215-223
15. Bolden-Watson C., and Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52 (1993) 1023-1029
16. Bradley C. Behaviour of children receiving benzedrine. Am J Psychiatr 94 (1937) 577-585
17. Butcher S.P., Liptrot J., and Aburthnott G.W. Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci Lett 122 (1991) 245-248
18. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Leucke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacol 27 (2002) 699-711
19. Cadoni C., Pinna A., Russi G., Consolo S., and Di Chiara G. Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and c-fos immunohistochemistry. Neurosci 65 (1995) 1027-1039
20. Carboni E., Silvagni A., Valentini V., and Di Chiara G. Effect of amphetamine, cocaine and depolarization by high potassium on extracellular dopamine in the nucleus accumbens shell of SHR rats. An in vivo microdialysis study. Neurosci Biobehav Rev. 27 (2003) 653-659
21. Casey B.J., Nigg J.T., and Durston S. New potential leads in the biology and treatment of attention deficit-hyperactivity disorder. Curr Opin Neurol 20 (2007) 119-124
22. Castellanos F.X., Giedd J.N., Marsh W.L., Hamburger S.D., Vaituzis A.C., Dickstein D.P., et al. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatr 53 (1996) 607-616
23. Castellanos F.X. Neuroimaging studies of ADHD. In: Solanto M., Arnsten A., and Castellanos F. (Eds). Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (2001), Oxford University Press, New York 243-258
24. Cheetham S.C., Kulkarni R.S., Rowley H.L., and Heal D.J. The SH rat model of ADHD has profoundly different catecholaminergic responses to amphetamine's enantiomer compared with Sprague-Dawleys. Society for Neurosciences (2007) Abstract 386.7
25. Chouinard G., Annable L., and Bradwejn J. An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol 83 (1984) 126-128
26. Cohen P., Cohen J., Kasen S., Velez C.N., Hartmark C., Johnson J., et al. An epidemiological study of disorders in late childhood and adolescence: I. age- and gender-specific prevalence. J Child Psychol Psychiatr 34 (1993) 851-867
27. 3H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention-deficit hyperactivity disorder. Neurochem Res. 20 (1995) 427-433
28. 11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacol 131 (1997) 71-78
29. Dougherty D.D., Bonab A.A., Spencer T.J., Rauch S.L., Madras B.K., and Fischman A.J. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354 (1999) 2132-2133
30. Drolet G., Proulx K., Pearson D., Rochford J., and Deschepper C.F. Comparisons of behavioral and neurochemical characteristics between WKY, WKHA, and Wistar rat strains. Neuropsychopharmacol 27 (2002) 400-409
31. Durston S. A review of the biological bases of ADHD: what have we learned from imaging studies?. Ment Retard Dev Disabil Res Rev 9 (2003) 184-195
32. Easton N., Steward C., Marshall F., Fone K., and Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 52 (2007) 405-414
33. Ernst M., Zametkin A.J., Matochik J.A., Jons P.H., and Cohen R.M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 18 (1998) 5901-5907
34. 18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatr 156 (1999) 1209-1215
35. Ferris R.M., Tang F.L.M., and Maxwell R.A. A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J Pharmacol Exp Ther 181 (1972) 407-416
36. Floor E., and Meng L. Amphetamine releases dopamine from synaptic vesicles by dual mechanisms. Neurosci Lett 215 (1996) 53-56
37. Florin S.M., Kuczenski R., and Segal D.S. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pre-treatment. Brain Res 654 (1994) 53-62
38. Fujita S., Okutsu H., Yamaguchi H., Nakamura S., Adachi K., Saigusa T., and Koshikawa N. Altered pre- and postsynaptic dopamine receptor functions in spontaneously hypertensive rat: an animal model of attention-deficit hyperactivity disorder. J Oral Sci. 45 (2003) 75-83
39. Gattu M., Pauly J.R., Boss K.L., Summers J.B., and Buccafusco J.J. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors. Part I. Brain Res. 771 (1997) 89-103
40. Gattu M., Terry Jr. A.V., Pauly J.R., and Buccafusco J.J. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors. Part II. Brain Res 771 (1997) 104-114
41. Géranton S.M., Heal D.J., and Stanford S.C. Differences in the mechanisms that increase norepinephrine efflux after administration of d-amphetamine: a dual-probe microdialysis study in rat frontal cortex and hypothalamus. Br J Pharmacol 139 (2003) 1441-1448
42. Géranton S.M., Heal D.J., and Stanford S.C. Norepinephrine clearance differs in the frontal cortex and hypothalamus: a dual-probe microdialysis study in feely-moving rats. Neurosci Lett 350 (2003) 157-160
43. Géranton S.M., Heal D.J., and Stanford S.C. 5-HT has contrasting effects in the frontal cortex, but not the hypothalamus, on changes in norepinephrine efflux induced by the monoamine releasing-agent, d-amphetamine, and the reuptake inhibitor, BTS 54 354. Neuropharmacol 46 (2004) 511-518
44. Gross M.D. A comparison of d-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction. Dis Nerv Syst 37 (1976) 14-16
45. Gundlah C., Martin K.F., Heal D.J., and Auerbach S.B. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 283 (1997) 581-591
46. Halperin J.M., Newcorn J.H., Koda V.H., Pick L., McKay K.E., and Knott P. Noradrenergic mechanisms in ADHD children with and without reading disabilities: a replication and extension. J Am Acad Child Adolesc Psychiatr 36 12 (1997) 1688-1697
47. Heal D.J., and Pierce D.M. Methylphenidate and its isomers. Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20 (2006) 713-738
48. 3H]dopamine from superfused rat striatal slices: predictive value for detecting stimulant drugs of abuse. Br J Pharmacol 117 (1996) 325P
49. Heal D.J., Cheetham S.C., Prow M.R., Martin K.F., and Buckett W.R. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 125 (1998) 301-308
50. Heal D.J., Aspley M., Prow M.R., Jackson H.C., Martin K.F., and Cheetham S.C. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenflluramine. Int J Obes 22 (1998) S18-S28
51. Heal D.J., Cheetham S.C., Kulkarni R.S., and Rowley H.L. Characterisation of the catecholaminergic profiles of methylphenidate and its enantiomers in an animal model of ADHD by in vivo microdialysis. Society for Neurosciences (2006) Abstract 97.0/0047
52. Hecht K., Poppei M., Hecht T., Postnow J.W., Moritz V., and Baumann R. Learning and memory processes during postnatal ontogenesis in rats with spontaneous hypertension. Acta Biol Med Ger 37 (1978) 1471-1478
53. 3H]norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194 (1975) 47-56
54. Hernandez C.M., Høifødt H., and Terry A.V. Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression. J Psychiatr Neurosci 28 (2003) 197-209
55. Holmes J.C., and Rutledge C.O. Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain. Biochem Pharmacol 25 (1976) 447-451
56. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol Biol Psychiatr 6 (1982) 277-295
57. Johansen E.B., Aase H., Meyer A., and Sagvolden T. Attention-deficit/hyperactivity disorder (ADHD) behaviour explained by dysfunctioning reinforcement and extinction processes. Behav Brain Res 130 (2002) 37-45
58. Knardahl S., and Sagvolden T. Open-field behaviour of spontaneously hypertensive rats. Behav Neural Biol 27 (1979) 178-200
59. Knardahl S., and Karlsen K. Passive-avoidance behavior of spontaneously hypertensive rats. Behav Neural Biol 42 (1984) 9-22
60. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68 (1997) 2032-2037
61. Kuczenski R., Segal D.S., Cho A.K., and Melega W. Hippocampus norephinephrine, caudate dopamine and serotonin, and behavioural responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15 (1995) 1308-1317
62. Kula N.S., and Baldessarini R.J. Lack of increase in dopamine transporter binding or function in rat brain tissue after treatment with blockers of neuronal uptake of dopamine. Neuropharmacol 30 (1991) 89-92
63. Kulkarni R.S., Rowley H.L., Cheetham S.C., and Heal D.J. Differential effects of d- and l-threo-methylphenidate on extracellular levels of dopamine in the striatum and norepinephrine in the frontal cortex: a dual-probe microdialysis study in freely-moving spontaneously hypertensive rats. In: Di Chiara G., Carboni E., Valentini V., Acquas E., and Bassareo V And Cardoni C. (Eds). Monitoring Molecules in Neuroscience, Proceedings of the 11th International Conference on In Vivo Methods (2006), University of Cagliari, Cagliari, Italy 499-501
64. Lahey B.B., Applegate B., McBurnett K., Biederman J., Greenhill L., Hynd G.W., et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatr 151 (1994) 1673-1685
65. Levin E.D., Wilkerson A., Jones J.P., Christopher N.C., and Briggs S.J. Prenatal nicotine effects on memory in rats: pharmacological and behavioral challenges. Brain Res Dev Brain Res 97 (1996) 207-215
66. 14C]acetylcholine release from nucleus caudatus slices: differences between spontaneously hypertensive rats and Wistar-Kyoto rats. Brain Res 509 (1990) 266-272
67. 2 receptor agonist quinpirole on the in vivo release of dopamine in the caudate nucleus of hypertensive rats. Eur J Pharmacol 201 (1991) 125-133
68. Maisonneuve I.M., Keller R.W., and Glick S.D. Interactions of ibogaine and of d-amphetamine: in vivo microdialysis and motor behaviour in rats. Brain Res 579 (1992) 87-92
69. Mantle T.J., Tipton K.F., and Garrett N.J. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 25 (1976) 2073-2077
70. McCarty R., and Kopin I.J. Patterns of behavioural development in spontaneously hypertensive rats and Wistar-Kyoto normotensive controls. Dev Psychobiol 12 (1979) 239-243
71. Meier R., Gross F., and Tripod J. Ritalin, a new synthetic compound with specific analeptic components. Klin Wochenschr 32 (1954) 445-450
72. McKeon T.W., and Hendley E.D. Brain monoamines and metabolites in hypertensive and hyperactive rat strains. Clin Exp Hypertens A 10 (1988) 971-994
73. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) E83-E92
74. Michelson D., Allen A.J., Busner J., Casat C., Dunn D., Kratochvil C., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159 (2002) 1896-1901
75. Miele M., Mura M.A., Enrico P., Esposito G., Serra P.A., Migheli R., et al. On the mechanisms of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats. Br J Pharmacol 129 (2000) 582-588
76. Mook D.M., and Neuringer A. Different effects of amphetamine on reinforced variations versus repetitions in spontaneously hypertensive rats (SHR). Physiol Behav 56 (1994) 939-944
77. Mori S., Kato M., and Fujishima M. Impaired maze learning and cerebral glucose utilization in aged hypertensive rats. Hypertension 25 (1995) 545-553
78. Moser M.B., Moser E.I., Wultz B., and Sagvolden T. Component analyses differentiate between exploratory behaviour of spontaneously hypertensive rats and Wistar-Kyoto rats in a two-compartment free-exploration open field. Scand J Psychol 29 (1988) 200-206
79. Myers M.M., Musty R.E., and Hendley E.D. Attenuation of hyperactivity in the spontaneously hypertensive rat by amphetamine. Behav Neural Biol 34 (1982) 42-54
80. Nakamura-Palacios E.M., Caldas C.K., Fiorini A., Chagas K.D., Chagas K.N., and Vasquez E.C. Deficits of spatial learning and working memory in spontaneously hypertensive rats. Behav Brain Res 74 (1996) 217-227
81. Oades R.D. Attention deficit disorder with hyperactivity (ADDH): the contribution of catecholaminergic activity. Prog. Neurobiol 29 4 (1987) 365-391
82. Oades R.D. Dopamine may be 'hyper' with respect to norepinephrine metabolism, but 'hypo' with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder. Behav Brain Res 130 (2002) 97-102
83. Oades R.D., Sadile A.G., Sagvolden T., Viggiano D., Zuddas A., Devoto P., et al. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 8 (2005) 122-131
84. Palkowitz A.D., Steinberg M.I., Thrasher K.J., Reel J.K., Hauser K.L., Zimmerman K.M., et al. Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists. J Med Chem 37 (1994) 4508-4521
85. Panizzon L. The preparation of pyridines- and piperidine-arylacetonitriles and the alkylation products of transformations (part I). Helv Chim Acta 27 (1944) 1748-1756
86. Patrick K.S., Caldwell R.W., Ferris R.M., and Breese G.R. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241 (1987) 152-158
87. Richelson E., and Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104 (1984) 227-286
88. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001) 32-41
89. Rowley H.L., Butler S.A., Prow M.R., Dykes S.G., Aspley S., Kilpatrick I.C., et al. Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 38 (2000) 167-176
90. Russell V.A. The nucleus accumbens motor-limbic interface of the spontaneously hypertensive rat as studied in vitro by the superfusion slice technique. Neurosci Biobehav Rev 24 (2000) 133-136
91. Russell V.A. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res 130 (2002) 191-196
92. Russell V.A. In vitro glutamate-stimulated release of dopamine from nucleus accumbens core and shell of spontaneously hypertensive rats. Metab Brain Dis 18 (2003) 161-168
93. Russell V.A., and Wiggins T.M. Increased glutamate-stimulated norepinephrine release from prefrontal cortex slices of spontaneously hypertensive rats. Metab Brain Dis 15 (2000) 297-304
94. Russell V., de Villiers A., Sagvolden T., Lamm M., and Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Brain Res 676 (1995) 343-351
95. 3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 94 (1998) 163-171
96. Russell V., Allie S., and Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res. 117 (2000) 69-74
97. Russell V.A., Sagvolden T., and Johansen E.B. Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 1 (2005) 9
98. Sagvolden T. Behavioural validation of the spontaneously hypertensive rat (SHR) as an animal model of Attention-Deficit/Hyperactivity Disorder (AD/HD). Neurosci Biobehav Rev 24 (2000) 31-39
99. Sagvolden T. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct 2 (2006) 41
100. Sagvolden T., and Xu T. d-Amphetamine reduces overactivity and impulsiveness and l-amphetamine improves poor sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct 4 (2008) 3
101. Sagvolden T., Metzger M.A., Schiørbeck H.K., Rugland A.L., Spinnangr I., and Sagvolden G. The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants. Behav Neural Biol 58 (1992) 103-112
102. Sagvolden T., Hendley E.D., and Knardahl S. Behavior of hypertensive and hyperactive rat strains: hyperactivity is not unitarily determined. Physiol Behav 52 (1992) 49-57
103. Sagvolden T., Pettersen M.B., and Larsen M.C. Spontaneously hypertensive rats (SHR) as a putative animal model of childhood hyperkinesis: SHR behaviour compared to four other rat strains. Physiol Behav 54 (1993) 1047-1055
104. Setescak L.L., Dekow F.W., Kitzen J.M., and Martin L.L. (+/-)-4-Aryl-4,5-dihydro-3H-1,3-benzodiazepines. 3 2-Phenyl and 2-amino analogues as potential antihypertensive agents. J Med Chem 27 (1984) 401-404
105. Sharp T., Zetterström T., Ljungberg T., and Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 401 (1987) 322-330
106. Sieg K.G., Gaffney G.R., Preston D.F., and Hellings J.A. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder. Clin Nucl Med 20 (1995) 55-60
107. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130 (2002) 65-71
108. Spencer T., Biederman J., Wilens T., Harding M., O Donnell D., and Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatr 35 (1996) 409-432
109. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatr 155 (1998) 693-695
110. Sulzer D., and Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron (1990) 797-808
111. Sutterer J.R., DeVito W.J., and Rykaszewski I. Developmental aspects of 2-way shuttlebox avoidance in the spontaneously hypertensive and normotensive rat. Dev Psychobiol 14 (1981) 405-414
112. Sutterer J.R., Perry J., and DeVito W. Two-way shuttle box and lever-press avoidance in the spontaneously hypertensive and normotensive rat. J Comp Physiol Psychol 94 (1980) 155-163
113. Swanson C.J., Perry K.W., Koch-Krueger S., Katner J., Svensson K.A., and Bymaster F.P. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacol 50 (2006) 755-760
114. Szporny L., and Görög P. Investigations into the correlations between monoamine oxidase inhibition and other effects due to methylphenidate and its stereoisomers. Biochem Pharmacol 8 (1961) 2630-2638
115. Tan M., and Appleton R. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy. Arch Dis Child 90 (2005) 57-59
116. Taylor E., Sandberg S., Thorley G., and Giles S. The epidemiology of childhood hyperactivity. Maudsley Monographs no 33 (1991), Oxford University Press, Oxford 93-113
117. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatr 56 (1999) 1073-1086
118. van den Bergh F.S., Bloemarts E., Chan J.S., Groenink L., Olivier B., and Oosting R.S. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol Biochem Behav 83 (2006) 380-390
119. Vickroy T.W., and Johnson K.M. Similar dopamine-releasing effects of phencyclidine and non-amphetamine stimulants in striatal slices. J Pharmacol Exp Ther 233 (1982) 669-674
120. Wall S.C., Gu H., and Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 47 (1995) 544-550
121. Watanabe Y., Fujita M., Ito Y., Okada T., Kusuoka H., and Nishimura T. Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 38 (1997) 470-474
122. Westerink B.H.C., Tuntler J., Damsma G., Rollema H., and de Vries J.B. The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn-Schmiedebergs Arch Pharmacol 336 (1987) 502-507
123. Wilens T.E., Spencer T.J., Biederman J., Girard K., Doyle R., Prince J., et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158 (2001) 282-288
124. Wilens T.E., Haight B.R., Horrigan J.P., Hudziak J.J., Rosenthal N.E., Connor D.F., et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomised, placebo-controlled study. Biol Psychiatr 57 (2005) 793-801
125. Willcutt E.G., Pennington B.F., Chhabildas N.A., Friedman M.C., and Alexander J. Psychiatric comorbidity associated with DSM-IV ADHD in non-referred sample of twins. J Am Acad Child Adolesc Psychiatr 38 (1999) 1355-1362
126. Wultz B., and Sagvolden T. The hyperactive spontaneously hypertensive rat learns to sit still, but not to stop bursts of responses with short inter-response times. Behav Genet 22 (1992) 415-433
127. Wultz B., Sagvolden T., Moser E.I., and Moser M.B. The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behaviour. Behav Neural Biol 53 (1990) 88-102
128. Wyss J.M., Fisk G., and van Groen T. Impaired learning and memory in mature spontaneously hypertensive rats. Brain Res 592 (1992) 135-140
129. Zetterström T., Sharp T., Marsden C.A., and Ungerstedt U. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem 41 (1983) 1769-1773